AbbVie reported Phase 3 success for etentamig, a dual-acting bispecific antibody for multiple myeloma, meeting the trial’s main goal of improving progression outcomes versus standard regimens. The company said the study interim checkpoint prompted unblinding after independent trial monitors detected a significant difference. The Phase 3 trial enrolled 421 participants, with 393 evaluable at an average follow-up of 11 months after trial entry. AbbVie reported etentamig helped people who had progressed on two or more prior lines live longer without progression. The company also emphasized a safety profile with low rates of serious immune responses common to drugs in the same class. AbbVie is positioning etentamig as potentially enabling broader use in community oncology settings by reducing the monitoring burden typically required for bispecific-related adverse events.